Sitagliptin as a Novel Treatment Agent for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus
The DOI matches its Crossref record.
Abstract
BACKGROUND/AIMS: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver injury, and is considered as the hepatic manifestation of metabolic syndrome. However, no effective drug therapy for NAFLD has been established yet. In the present study, we evaluated the efficacy of 4 months of treatment with sitagliptin in NAFLD patients with type 2 diabetes mellitus (DM). METHODOLOGY: We evaluated 30 NAFLD patients with type 2 DM. NAFLD was diagnosed by ultrasonography. The patients were administered sitagliptin (50mg/body/day) for 4 months. RESULTS: significant decreases of the plasma glucose and serum HbA1c, AST, ALT and γ-GTP levels were observed after 4 months of treatment with sitagliptin. CONCLUSIONS: In this study, not only the parameters of diabetes, but also those of liver tests were improved by the treatment with sitagliptin. Our study demonstrated the efficacy of sitagliptin in NAFLD patients with type 2 DM, suggesting that a large-scale clinical trial is warranted in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
Non-alcoholic fatty liver disease and diabetes
Hazlehurst, J. M., Woods, C., Marjot, T., Cobbold, J. F., & Tomlinson, J. W. (2016) · Metabolism · doi:10.1016/j.metabol.2016.01.001 · Cited by 527
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
Röhrborn, D. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00386 · Cited by 440
NAFLD in Asia—as common and important as in the West
Farrell, G. C., Wong, V. W.-S., & Chitturi, S. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.34 · Cited by 432
Treatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Dipeptidyl peptidase-4: A key player in chronic liver disease
Itou, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i15.2298 · Cited by 177
Karlas, T., Petroff, D., Garnov, N., Böhm, S., Tenckhoff, H., Wittekind, C., Wiese, M., Schiefke, I., Linder, N., Schaudinn, A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091987 · Cited by 168
“Moreover, detailed quantification of steatosis is important in estimating the therapeutic success of different pharmaceutical treatment options in NAFLD [9,10].”
BackgroundPharmacological management of nonalcoholic fatty liver disease
Barb, D., Portillo-Sanchez, P., & Cusi, K. (2016) · Metabolism · doi:10.1016/j.metabol.2016.04.004 · Cited by 114
Watanabe, T., Tamura, Y., Kakehi, S., Funayama, T., Gastaldelli, A., Takeno, K., Kawaguchi, M., Yamamoto, R., Sato, F., Ikeda, S., et al. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12262 · Cited by 31
Attaran, F., Emami, S., Sohrabi, M., Malek, M., Ajdarkosh, H., Khoonsari, M., Ismail-Beigi, F., & Khamseh, M. E. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02948-4 · Cited by 22
“Earlier studies have shown that anti-hyperglyce-mic agents can improve abnormal liver enzymes [6–8].”
Background
Metadata
- Authors
- Iwasaki, T., Yoneda, M., Inamori, M., Shirakawa, J., Higurashi, T., Maeda, S., Terauchi, Y., & Nakajima, A.
- Venue
- Hepatogastroenterology
- Publisher
- Update Medical Publishing
- Published
- 2011-10-12
- Volume
- 58
- Issue
- 112
- Pages
- 2103-5
- ISSN
- 0172-6390 (ISSN-L)
- OpenAlex
- W2026049223
- Cited by
- 124
- References
- 0
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.